Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial

Douillard, J Y; Cunningham, D; Roth, Arnaud; Navarro, M; James, R D; Karasek, P; Jandik, P; Iveson, T; Carmichael, J; Alakl, M; Gruia, G; Awad, L; Rougier, P

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial
Authors		Douillard, J Y Cunningham, D Roth, Arnaud Navarro, M James, R D Karasek, P Jandik, P Iveson, T Carmichael, J Alakl, M Gruia, G Awad, L Rougier, P show all authors [1 - 13]
Published in		The Lancet. 2000, vol. 355, no. 9209, p. 1041-7
Abstract		Irinotecan is active against colorectal cancer in patients whose disease is refractory to fluorouracil. We investigated the efficacy of these two agents combined for first-line treatment of metastatic colorectal cancer.
Keywords		Adenocarcinoma/drug therapy/mortality/pathology — Adult — Aged — Antineoplastic Agents, Phytogenic/administration & dosage/adverse effects — Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use — Camptothecin/administration & dosage/adverse effects/analogs & derivatives — Colorectal Neoplasms/drug therapy/mortality/pathology — Female — Fluorouracil/administration & dosage/adverse effects — Humans — Leucovorin/administration & dosage/adverse effects — Male — Middle Aged — Neoplasm Staging — Quality of Life — Survival Rate
Identifiers		PMID: 10744089
Full text		Article (Published version) (106 Kb) - Limited access to UNIGE Other version: http://www.sciencedirect.com/science/article/pii/S0140673600020341#
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine Faculté de médecine / Section de médecine clinique / Département de chirurgie
Research group		Groupe Roth Arnaud (oncologie) (285)
Citation (ISO format)		DOUILLARD, J Y et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. In: The Lancet, 2000, vol. 355, n° 9209, p. 1041-7. https://archive-ouverte.unige.ch/unige:55094